cidofovir anhydrous has been researched along with cyclosporine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Böhringer, D; Cartsburg, O; De Clercq, E; Godehardt, E; Hillenkamp, J; Reinhard, T; Roggendorf, M; Ross, RS; Sundmacher, R | 2 |
| Hillenkamp, J; Reinhard, T; Sundmacher, R | 1 |
| Ait Arkoub, Z; Arnulf, B; Chebbi, F; Fillet, AM; Lefrere, F; Varet, B | 1 |
| Chakrabarti, S; Collingham, KE; Fegan, CD; Milligan, DW; Osman, H | 1 |
| Cosio, FG; Fidler, ME; Gloor, JM; Griffin, MD; Khamash, HA; Lager, DJ; Larson, TS; Lewin, M; Mahale, AS; Rule, AD; Schwab, TR; Stegall, MD; Textor, SC; Wadei, HM | 1 |
| Benninghoff, U; Friedrich, W; Hönig, M; Schulz, A; Schütz, C | 1 |
| Bose, N; Chowdhury, K; Pal, P; Poddar, A; Saha, A | 1 |
| Aydamirov, AS; Erdem, E; Harbiyeli, II; Ozturk, G; Yagmur, M; Yarkin, F | 1 |
4 review(s) available for cidofovir anhydrous and cyclosporine
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Prospects for therapy and prevention of adenovirus keratoconjunctivitis].
Topics: Adenovirus Infections, Human; Adolescent; Adrenal Cortex Hormones; Adult; Antiviral Agents; Child; Child, Preschool; Cidofovir; Cyclosporine; Cytosine; Humans; Immunosuppressive Agents; Interferons; Keratitis; Keratoconjunctivitis, Infectious; Ophthalmic Solutions; Organophosphonates; Organophosphorus Compounds; Recurrence; Time Factors | 2001 |
Experience with Cidofovir as an adjunctive therapy in a patient of adenovirus-induced macrophage activation syndrome in systemic arthritis.
Topics: Adenoviridae; Adenoviridae Infections; Antiviral Agents; Arthritis, Juvenile; Child, Preschool; Cidofovir; Combined Modality Therapy; Cyclosporine; Female; Humans; Macrophage Activation Syndrome; Methylprednisolone; Pneumonia, Viral; Radiography, Thoracic | 2020 |
2 trial(s) available for cidofovir anhydrous and cyclosporine
| Article | Year |
|---|---|
Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study.
Topics: Acute Disease; Adenovirus Infections, Human; Adenoviruses, Human; Administration, Topical; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cidofovir; Cyclosporine; Cytosine; DNA Primers; DNA, Viral; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Eye Infections, Viral; Female; Humans; Immunosuppressive Agents; Keratoconjunctivitis; Male; Middle Aged; Ophthalmic Solutions; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Polymerase Chain Reaction; Treatment Outcome | 2001 |
The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study.
Topics: Acute Disease; Adenovirus Infections, Human; Adenoviruses, Human; Adult; Aged; Aged, 80 and over; Antiviral Agents; Cidofovir; Conjunctiva; Cyclosporine; Cytosine; DNA Primers; DNA, Viral; Drug Therapy, Combination; Eye Infections, Viral; Eyelids; Female; Humans; Immunosuppressive Agents; Keratoconjunctivitis; Male; Middle Aged; Ophthalmic Solutions; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Polymerase Chain Reaction; Safety | 2002 |
11 other study(ies) available for cidofovir anhydrous and cyclosporine
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Multiple herpes simplex virus infections with various resistance patterns in a matched unrelated donor transplant recipient.
Topics: Acyclovir; Antineoplastic Agents, Alkylating; Antiviral Agents; Bone Marrow Transplantation; Cidofovir; Combined Modality Therapy; Cyclosporine; Cytarabine; Cytomegalovirus Infections; Cytosine; Drug Resistance, Viral; Fatal Outcome; Foscarnet; Graft vs Host Disease; Herpes Genitalis; Herpes Simplex; Humans; Hydroxyurea; Immunocompromised Host; Immunosuppressive Agents; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Organophosphonates; Organophosphorus Compounds; Simplexvirus; Transplantation Conditioning; Whole-Body Irradiation | 2001 |
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Topics: Adult; Antiviral Agents; Cidofovir; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA, Viral; Drug Evaluation; Eye Infections, Viral; Female; Foscarnet; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Polymerase Chain Reaction; Probenecid; Recurrence; Safety; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Uveitis, Anterior; Viral Load; Viremia; Vomiting | 2001 |
Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN).
Topics: Adult; Antiviral Agents; Biopsy; Cidofovir; Cyclosporine; Cytosine; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Kidney Diseases; Kidney Transplantation; Male; Middle Aged; Organophosphonates; Polyomavirus Infections; Postoperative Complications; Treatment Outcome | 2006 |
Results and long-term outcome in 39 patients with Wiskott-Aldrich syndrome transplanted from HLA-matched and -mismatched donors.
Topics: Antiviral Agents; Child; Child, Preschool; Chimerism; Cidofovir; Cyclosporine; Cytosine; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Histocompatibility; HLA Antigens; Humans; Immunosuppressive Agents; Infant; Living Donors; Male; Organophosphonates; Treatment Failure; Wiskott-Aldrich Syndrome | 2009 |
In Vitro efficacy of cyclosporine a and various antiseptics and antiviral drugs on adenovirus genotype 8, a common cause of epidemic keratoconjunctivitis.
Topics: Adenoviridae; Adenoviridae Infections; Anti-Infective Agents, Local; Antiviral Agents; Chlorhexidine; Cidofovir; Cyclosporine; Ganciclovir; Genotype; Humans; Keratoconjunctivitis; Povidone-Iodine | 2023 |